DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA. This action is responsive to papers filed 03/12/2026. Claims 1, 8 and 15 have been amended. Claims 2-3 and 9-10 have been newly canceled and no claims have been newly added. Claims, 1, 4-8, 11-19 are currently pending. Election/Restrictions Applicant’s election without traverse of Group II (claims 8-14) in the reply filed on 03/12/2026 is acknowledged. Claims 1, 4-7, 15-19 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 03/12/2026. The restriction requirement is made Final. Claims 8 and 11-14 have been examined on their merits. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b ) CONCLUSION.— The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the appl icant regards as his invention. Claim 14 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 14 recites the limitation "the culture" in lines 1-2. There is insufficient antecedent basis for this limitation in the claim. It is unclear if the claim is referring to the first culture that has forskolin added to it or the second culture that is formed from the cells removed after the addition of the forskolin. For examination purposes “the culture” is interpreted as referring to either the first or second culture after the addition of the forskolin, but before or after the removal of the cells from the first culture. Appropriate correction is required. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis ( i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale , or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 8 and 11-14 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Jang et al (BMC, Cell Biology, 2010-from IDS filed 10/18/2023). Regarding claim 8 , 11-14 , Jang disclose culturing human adipose-derived mesenchymal stem cells ( hADSCs ) in a first culture medium containing 100 ng/mL bFGF for 7 days and then culturing these cells in a second culture medium containing 10 µM forskolin for 7 days , and then removing these cells so as to obtain a second cell culture for additional testing (page 10, paragraph bridging columns 1-2, page 10 column 2–page11 column 1). Therefore, the teaching of Jang et al anticipates Applicant’s invention as claimed. Conclusion No claims are allowed. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Kim et al., WO 2013/119045-A1 foreign patent document and machine translation Seong et al., KR 2011-0066443 (A) machine translation Any inquiry concerning this communication or earlier communications from the examiner should be directed to FILLIN "Examiner name" \* MERGEFORMAT LAURA J SCHUBERG whose telephone number is FILLIN "Phone number" \* MERGEFORMAT (571)272-3347 . The examiner can normally be reached FILLIN "Work Schedule?" \* MERGEFORMAT 8:30-5:00 EST . Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, FILLIN "SPE Name?" \* MERGEFORMAT James (Doug) Schultz can be reached at FILLIN "SPE Phone?" \* MERGEFORMAT 571-272-0763 . The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. FILLIN "Examiner Stamp" \* MERGEFORMAT LAURA J. SCHUBERG Primary Examiner Art Unit 1631 /LAURA SCHUBERG/ Primary Examiner, Art Unit 1631